Spotlight
Clinical
Conferences
CME/CE
Bispecific Antibodies in the Treatment of Multiple Myeloma: An Expert Case-Based Discussion : Episode 10
Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives
Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.
EP: 1.Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab
EP: 2.Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
EP: 3.Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM
EP: 4.BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS
EP: 5.BCMA-Targeting Bispecific Antibodies in RRMM: Managing ICANS and Infections
EP: 6.Patient Case 2: Managing Heavily Pre-Treated MM With Talquetamab
EP: 7.Appropriate Patient Selection for Talquetamab in Relapsed/Refractory MM
EP: 8.Patient Case 3: Cevostamab in a Patient with MM who Progressed on Multiple Lines of Therapy
EP: 9.Appropriate Patient Selection for Cevostamab in Relapsed/Refractory MM
Now Viewing
EP: 10.Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives
EP: 11.Bispecific Antibodies Promise to be ‘Transformative’ in Multiple Myeloma
Related Videos
Related Content
